Dare Bioscience Inc Stock Price, News & Analysis

Daré Bioscience (NASDAQ: DARE) will feature its President and CEO, Sabrina Martucci Johnson, at the Virtual Global Healthcare Conference from September 27 to 30, 2021. Johnson's presentation is scheduled for September 30 at 12:40 p.m. ET. Investors can access a live webcast at this link, with an archived version available until October 15, 2021, on the company's investor website. Daré is known for its commitment to advancing innovative women’s health products, including Ovaprene® and Sildenafil Cream, 3.6%.

Daré Bioscience, Inc. (NASDAQ: DARE) announced that its President and CEO, Sabrina Martucci Johnson, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13 at 7:00 a.m. ET. An archived version will be accessible until September 29, 2021. Daré specializes in women’s health and is developing innovative therapies, including Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1. More information can be found on their website.

Daré Bioscience (NASDAQ: DARE) announces its participation in the Women’s Health Innovation Summit in Boston on September 14-15, 2021. The panel will focus on optimizing study enrollment during the COVID-19 pandemic, specifically discussing the DARE-BVFREE Phase 3 study of DARE-BV1, an investigational treatment for bacterial vaginosis. The study, initiated in 2020, successfully enrolled 307 women and met its primary endpoint, showing clinical cure rates of 70-81%, significantly higher than current FDA-approved treatments. A new drug application for DARE-BV1 has been submitted to the FDA, with a review date set for December 7, 2021.

Daré Bioscience announces a presentation by Dr. David Friend at the EMAS 13th European Congress on Menopause, from September 8-10, 2021. He will present data from the Phase 1 clinical trial of DARE-HRT1, a novel intravaginal ring delivering bio-identical estradiol and progesterone over 28 days. The results support DARE-HRT1’s potential to be the first FDA-approved hormone therapy for menopause symptoms, potentially transforming treatment options. For more information, visit Daré's Investor Relations.

Daré Bioscience (NASDAQ: DARE) reported strong advancements in women’s health innovation with its Q2 2021 financial results, marking a productive year. The company submitted a New Drug Application for DARE-BV1 and secured Priority Review by the FDA, targeting a PDUFA date of December 7, 2021. Clinical studies are underway for Sildenafil Cream and DARE-HRT1. Financially, cash equivalents increased to $9.1 million, with net cash from financing activities nearing $24.6 million. However, the company reported a comprehensive loss of $9.2 million for Q2 2021, up from $7.1 million YoY.

Daré Bioscience (NASDAQ: DARE) announced that the FDA has accepted its New Drug Application (NDA) for DARE-BV1, a treatment for bacterial vaginosis, granting it Priority Review with a PDUFA date set for December 7, 2021.

The NDA is backed by data from the DARE-BVFREE Phase 3 trial, showing clinical cure rates of 70-81% after a single dose of DARE-BV1. If approved, the company plans a robust market launch in 2022, supported by strategic discussions and commercialization arrangements.

Daré Bioscience (NASDAQ: DARE) announced a conference call on August 12, 2021, at 4:30 PM ET to review its financial results for Q2 2021 and provide an update on company developments. Investors can access the call by dialing (844) 831-3031 for the U.S. or (443) 637-1284 internationally, with conference ID 5286254. The company focuses on women's health, offering innovative solutions like the hormone-free contraceptive Ovaprene and Sildenafil Cream for sexual arousal disorders. To learn more, visit darebioscience.com.

Daré Bioscience presented positive results from the DARE-BVFREE Phase 3 trial for DARE-BV1, targeting bacterial vaginosis in women. The study met its primary endpoint, achieving clinical cure rates between 70-81% with a single vaginal dose. This investigational hydrogel formulation includes clindamycin phosphate 2% and aims to provide a convenient alternative to current treatments. The company submitted a new drug application to the FDA in June 2021 and shared findings at the Controlled Release Society Annual Meeting on July 27, 2021.

Daré Bioscience, Inc. (NASDAQ: DARE) has entered into a Cooperative Research and Development Agreement (CRADA) with the NICHD for the Phase 3 study of Ovaprene®, a hormone-free monthly contraceptive. This collaboration will enable shared funding and expertise in conducting the pivotal study, which is expected to begin in 2022. Daré will contribute $5.5 million towards the study costs and aims to submit an Investigational Device Exemption (IDE) to the FDA in Q4 2021. If approved, Ovaprene could become the first monthly non-hormonal contraceptive for women.